Bayer announced that September 2024 in-market sales of Nubeqa® (Darolutamide), the prostrate cancer drug, has exceeded sales of €1 billion year-to-date making Darolutamide the first ever Orion-originated product to gain blockbuster status.
Orion, the globally operating Finnish pharmaceutical company, has a wide range of primary healthcare prescription drugs and other products for treatment and prevention of the commonest illnesses.
Their portfolio consists of a range of hundreds of products, but one of their innovations called Darolutamide, that was originally developed with the Bayer, has now reached this major milestone, which means that Orion will receive a large milestone payment under the terms of their partnership agreement.
The FDA approved Nubeqa in 2019. It is commonly used to treat prostate cancer along with a treatment that lowers testosterone. Testosterone is an androgen hormone that can help fuel the growth of prostate cancer. Treatments that lower testosterone, including certain medicines and surgeries, are often used to treat prostate cancer. But over time, as the cancer learns how to grow despite very low testosterone levels, these treatments may not work as well. Nubeqa works to block the effects of testosterone from reaching cancer cells. It belongs to a class of medicines called androgen receptor blockers, also known as anti-androgens. Nubeqa is a newer medicine in this class and is considered a second-generation anti-androgen.
